has ongoing alliances and collaborations with partners that enable us to develop a broad line of field-proven products that enhance the welfare and performance of poultry, swine, and other farm animals.

AbCelex translate scientific discoveries from the lab bench to the field, by going through proof-of-concept field trials to find and advance the most promising product candidates. These proof-of-concept studies often focus on epidemic and endemic diseases of animal health.

AbCelex core proprietary technology Platform is a targeted protein feed additive approach that have demonstrated the potential to establish a new paradigm to prevent and treat a number of bacterial infections at source in livestock.

Products

AbCelex core proprietary Technology Platform comprises a targeted protein feed additive approach with a demonstrated potential to establish a new paradigm in preventing and treating a number of bacterial infections at source in livestock.

AbCelex is currently developing several feed additive candidates against a number of microbial infections in broiler chickens. AbCelex’s lead product, NF-220, comprises a number of novel sdAb-based protein fragments with the potential to significantly reduce Campylobacter jejuni colonization and gastroenteritis in the GI tract of broiler when given as a feed additive or in drinking water.

Campylobacter jejuni is a food-borne pathogen commonly present in the poultry gut. Campylobacter is the leading global cause of food-borne illness, and a rising public health concern. Our results to-date have demonstrated an above 2 log reduction in the rate of Campylobacter jejuni colonization in the GI tract of broiler chickens treated with our products.

Additional sdAb-based protein fragments targeted at zoonotic bacteria with human health implications are under development at this time.

As a pre-revenue venture-funded start-up biotech company, it is the policy of AbCelex to pay up to 15% overhead or indirect costs on grants provided to universities in the U.S. and Canada.

AbCelex Policy on Indirect Costs Paid to Contract Research Organizations

As a pre-revenue venture-funded start-up biotech company, it is the policy of AbCelex to pay up to 15% overhead or indirect costs on grants provided to contract research organizations in the U.S. and Canada.